AbbVie Inc. (ABBV)
Largest Insider Buys in Sector
ABBV Stock Price History Chart
ABBV Stock Performance
About AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Insider Activity of AbbVie Inc.
Over the last 12 months, insiders at AbbVie Inc. have bought $0 and sold $93.32M worth of AbbVie Inc. stock.
On average, over the past 5 years, insiders at AbbVie Inc. have bought $19.8M and sold $72.69M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 750 shares for transaction amount of $51,750 was made by Durkin Brian L (VP, Controller) on 2020‑03‑30.
List of Insider Buy and Sell Transactions, AbbVie Inc.
| 2024-03-20 | Sale | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 21,082 0.0012% | $176.30 | $3.72M | -5.68% | |
| 2024-03-18 | Sale | Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | 58,949 0.0033% | $178.79 | $10.54M | -6.76% | |
| 2024-03-01 | Sale | RICHMOND TIMOTHY J. | EVP, CHIEF HR OFFICER | 75,680 0.0042% | $177.27 | $13.42M | -6.21% | |
| 2024-02-29 | Sale | Michael Robert A. | PRES & CHIEF OPERATING OFFICER | 68,879 0.0039% | $176.45 | $12.15M | -4.61% | |
| 2024-02-29 | Sale | Siatis Perry C | EVP, GC AND SECRETARY | 9,891 0.0006% | $177.39 | $1.75M | -4.61% | |
| 2024-02-29 | Sale | Buckbee Kevin K | SVP, CONTROLLER | 5,144 0.0003% | $176.65 | $908,688 | -4.61% | |
| 2024-02-28 | Sale | GONZALEZ RICHARD A | CHAIRMAN OF THE BOARD AND CEO | 138,616 0.0078% | $177.27 | $24.57M | -5.71% | |
| 2024-02-23 | Sale | Siatis Perry C | EVP, GC AND SECRETARY | 13,753 0.0008% | $177.51 | $2.44M | -5.53% | |
| 2024-02-23 | Sale | Reents Scott T | EVP, CHIEF FINANCIAL OFFICER | 14,140 0.0008% | $177.44 | $2.51M | -5.53% | |
| 2024-02-21 | Sale | SALEKI-GERHARDT AZITA | EVP, CHIEF OPERATIONS OFFICER | 52,870 0.003% | $173.71 | $9.18M | -3.75% | |
| 2023-12-26 | Sale | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 2,912 0.0002% | $154.72 | $450,545 | +8.39% | |
| 2023-08-01 | Sale | GONZALEZ RICHARD A | CHAIRMAN OF THE BOARD AND CEO | 60,000 0.0035% | $148.58 | $8.91M | +7.65% | |
| 2023-07-31 | Sale | GONZALEZ RICHARD A | CHAIRMAN OF THE BOARD AND CEO | 18,500 0.0011% | $149.15 | $2.76M | +6.71% | |
| 2023-04-25 | Sale | Sorg Elaine K. | SVP, US COMMERCIAL OPERATIONS | 6,130 0.0003% | $165.00 | $1.01M | -8.43% | |
| 2023-04-17 | Sale | Sorg Elaine K. | SVP, US COMMERCIAL OPERATIONS | 7,499 0.0004% | $161.67 | $1.21M | -6.32% | |
| 2023-04-03 | Sale | Sorg Elaine K. | 15,002 0.0008% | $160.03 | $2.4M | -5.03% | ||
| 2023-04-03 | Sale | Siatis Perry C | 3,520 0.0002% | $160.00 | $563,200 | -5.03% | ||
| 2023-03-13 | Sale | Stewart Jeffrey Ryan | 53,125 0.003% | $152.28 | $8.09M | +0.29% | ||
| 2023-03-01 | Sale | SALEKI-GERHARDT AZITA | 36,990 0.0021% | $154.48 | $5.71M | -2.01% | ||
| 2023-03-01 | Sale | Sorg Elaine K. | 15,003 0.0008% | $155.00 | $2.33M | -2.01% |
Insider Historical Profitability
| GONZALEZ RICHARD A | CHAIRMAN OF THE BOARD AND CEO | 519099 0.032% | $171.15 | 0 | 21 | |
| SALEKI-GERHARDT AZITA | 243944 0.0108% | $171.15 | 0 | 19 | ||
| Stewart Jeffrey Ryan | 60941 0.0035% | $171.15 | 1 | 8 | +37.99% | |
| Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 55903 0.0032% | $171.15 | 1 | 2 | +35.4% |
| Michael Robert A. | Vice Chairman | 98645 0.0021% | $171.15 | 0 | 6 | |
| RICHMOND TIMOTHY J. | 13837 0.0008% | $171.15 | 0 | 22 | ||
| Siatis Perry C | 10397 0.0006% | $171.15 | 0 | 5 | ||
| Buckbee Kevin K | SVP, CONTROLLER | 6983 0.0004% | $171.15 | 0 | 1 | |
| Reents Scott T | 27065 0% | $171.15 | 0 | 3 | ||
| Schumacher Laura J | Vice Chairman | 213003 0.0121% | $171.15 | 1 | 14 | +27.78% |
| CHASE WILLIAM J | EVP, Finance & Administration | 169552 0.0096% | $171.15 | 1 | 7 | +28.08% |
| SEVERINO MICHAEL | Vice Chairman | 152103 0.0086% | $171.15 | 0 | 7 | |
| ALBAN CARLOS | Vice Chairman | 114899 0.0065% | $171.15 | 0 | 9 | |
| LEONARD JOHN M. | SVP, Chief Scientific Officer | 107320 0.0061% | $171.15 | 0 | 2 | |
| HURWICH THOMAS A. | VP, Controller | 67276 0.0038% | $171.15 | 0 | 7 | |
| Gosebruch Henry O | EVP, Chief Strategy Officer | 41623 0.0024% | $171.15 | 1 | 6 | +30.67% |
| TILTON GLENN F | director | 39735 0.0023% | $171.15 | 1 | 0 | <0.0001% |
| Strom Carrie C | 37921 0.0021% | $171.15 | 0 | 4 | ||
| Sorg Elaine K. | SVP, US COMMERCIAL OPERATIONS | 35330 0.002% | $171.15 | 0 | 10 | |
| AUSTIN ROXANNE S | director | 34483 0.002% | $171.15 | 4 | 3 | +31.05% |
| Durkin Brian L | VP, Controller | 19094 0.0011% | $171.15 | 3 | 3 | +36.78% |
| RAPP EDWARD J | director | 2875 0.0002% | $171.15 | 5 | 0 | +17.9% |
| WADDELL FREDERICK H | director | 2000 0.0001% | $171.15 | 1 | 0 | +22.15% |
Institutional Investor Ownership
| The Vanguard Group | $31.03B | 9.65 | 170.38M | +6.22% | +$1.82B | 0.59 | |
| BlackRock | $26.03B | 8.1 | 142.96M | -0.16% | -$40.72M | 0.59 | |
| State Street | $14.2B | 4.42 | 77.97M | -0.29% | -$41.92M | 0.61 | |
| JPMorgan Chase | $9.33B | 2.9 | 51.26M | -1.08% | -$102.03M | 0.84 | |
| Capital International Investors | $8.76B | 2.72 | 48.1M | +6.91% | +$566.44M | 1.78 | |
| Geode Capital Management | $6.81B | 2.12 | 37.49M | +1.29% | +$86.67M | 0.61 | |
| Morgan Stanley | $6.4B | 1.99 | 35.17M | +3.29% | +$203.8M | 0.5 | |
| Capital Research Global Investors | $5.7B | 1.77 | 31.3M | +3.27% | +$180.73M | 1.29 | |
| Charles Schwab | $4.12B | 1.29 | 22.72M | -7.09% | -$314.45M | 0.93 | |
| Northern Trust | $3.69B | 1.15 | 20.25M | -3.28% | -$124.89M | 0.62 | |
| BNY Mellon | $3.61B | 1.12 | 19.83M | -10.28% | -$413.62M | 0.68 | |
| Bank of America | $3.59B | 1.12 | 19.72M | +6.05% | +$204.79M | 0.35 | |
| Legal & General | $2.76B | 0.86 | 15.14M | -0.46% | -$12.8M | 0.65 | |
| Ameriprise Financial | $2.59B | 0.8 | 14.2M | +0.09% | +$2.2M | 0.72 | |
| Fidelity Investments | $2.27B | 0.71 | 12.49M | +12.6% | +$254.53M | 0.15 | |
| Franklin Templeton Investments | $2.03B | 0.63 | 11.15M | +47.23% | +$651.13M | 0.61 | |
| Janus Henderson | $1.98B | 0.62 | 10.9M | +12.84% | +$225.87M | 1.08 | |
| T. Rowe Price | $1.96B | 0.61 | 10.74M | +13.66% | +$235.13M | 0.24 | |
| UBS | $1.91B | 0.6 | 10.51M | -3.64% | -$72.28M | 0.58 | |
| Wells Fargo | $1.64B | 0.51 | 9.02M | -1.11% | -$18.38M | 0.44 | |
| Goldman Sachs | $1.62B | 0.5 | 8.89M | -16.33% | -$315.88M | 0.31 | |
| Nuveen | $1.62B | 0.5 | 8.89M | -2.42% | -$40.16M | 0.47 | |
| Ubs Asset Management Americas Inc | $1.59B | 0.5 | 8.75M | -1.01% | -$16.21M | 0.57 | |
| Massachusetts Financial Services Co Ma | $1.58B | 0.49 | 8.68M | +3.1% | +$47.52M | 0.47 | |
| Deutsche Bank | $1.53B | 0.48 | 8.39M | +15.76% | +$207.92M | 0.7 | |
| Royal Bank of Canada | $1.51B | 0.47 | 8.31M | -5.21% | -$83.17M | 0.36 | |
| Dimensional Fund Advisors | $1.5B | 0.47 | 8.22M | +2.49% | +$36.3M | 0.4 | |
| CalPERS | $1.22B | 0.38 | 6.68M | +9.83% | +$108.9M | 0.85 | |
| Amundi | $1.04B | 0.36 | 6.3M | -21.05% | -$276.66M | 0.44 | |
| State Farm | $1.09B | 0.34 | 5.99M | -3.39% | -$38.25M | 0.98 | |
| Dz Bank Ag Deutsche Zentral Genossenschafts Bank Frankfurt Am Main | $1.05B | 0.33 | 5.78M | +66.36% | +$419.67M | 1.19 | |
| Invesco | $968.45M | 0.3 | 5.32M | +0.95% | +$9.09M | 0.2 | |
| Swiss National Bank | $962.82M | 0.3 | 5.29M | -4.2% | -$42.23M | 0.66 | |
| AllianceBernstein | $891.42M | 0.28 | 4.9M | +16.73% | +$127.73M | 0.32 | |
| T Rowe Price Investment Management Inc | $880.8M | 0.27 | 4.84M | -0.11% | -$955,297.45 | 0.54 | |
| Envestnet Asset Management Inc | $850.36M | 0.26 | 4.67M | +2.18% | +$18.16M | 0.34 | |
| HSBC | $849.59M | 0.26 | 4.67M | +12.8% | +$96.44M | 0.61 | |
| PNC Financial Services | $806.4M | 0.25 | 4.43M | -6.38% | -$54.99M | 0.56 | |
| Capital World Investors | $796.36M | 0.25 | 4.37M | +249.05% | +$568.21M | 0.13 | |
| Sumitomo Mitsui Trust Holdings | $795.3M | 0.25 | 4.37M | -1.38% | -$11.12M | 0.55 | |
| Raymond James Associates | $786.93M | 0.25 | 4.32M | -4.17% | -$34.23M | 0.53 | |
| ClearBridge Investments | $756.58M | 0.24 | 4.15M | +5.38% | +$38.63M | 0.6 | |
| Nordea Investment Management Ab | $745.73M | 0.23 | 4.11M | -6.59% | -$52.66M | 0.88 | |
| Barclays | $691.12M | 0.22 | 3.8M | +16.32% | +$96.94M | 0.31 | |
| Bank of Montreal | $653.04M | 0.21 | 3.62M | -8.39% | -$59.78M | 0.2 | |
| Td Asset Management Inc | $632.62M | 0.2 | 3.47M | +156% | +$385.51M | 0.55 | |
| First Trust | $609.82M | 0.19 | 3.35M | -13.52% | -$95.35M | 0.62 | |
| Bahl & Gaynor Investment Counsel | $599.89M | 0.19 | 3.29M | -1.48% | -$9.04M | 3.34 | |
| Robeco Institutional Asset Management B.V. | $596.21M | 0.19 | 3.27M | +50.67% | +$200.51M | 1.3 | |
| RhumbLine Advisers | $592.83M | 0.18 | 3.26M | -0.83% | -$4.97M | 0.56 |